



Friday, June 7, 2019  
Cape Breton University  
Sydney, Nova Scotia

<p><b>DUAL ANTIPLATELET THERAPY (DAPT) FOR ACS, WHY DO PATIENTS RECEIVE DIFFERENT TREATMENTS AND WHEN TO STOP?</b></p> <p>At the conclusion of this session participants will be able to articulate why ACS patients are prescribed diverse treatment regimens and which patient populations should receive DAPT therapy beyond one year.</p>
<p><b>ACUTE MANAGEMENT OF ATRIAL FIBRILLATION (AFib) IN THE EMERGENCY DEPARTMENT</b></p> <p>At the completion of this session participants will be able to more effectively describe the optimal clinical management of AFib patients presenting in the ED as defined in the new 2018 CCS guidelines.</p>
<p><b>MY PATIENT REMAINS SYMPTOMATIC WITH ATRIAL FIBRILLATION. HOW TO MANAGE CHRONIC PROBLEMS, SYMPTOMS AND CHALLENGES WITH ANTICOAGULATION</b></p> <p>At the completion of this presentation participants will be able to better apply the body of clinical evidence to more effectively manage an AFib patient's exacerbations outside the ED.</p>
<p><b>SYNCOPE; WHEN IS IT JUST A FAINT AND WHEN DO I NEED TO WORRY</b></p> <p>At the conclusion of this session participants will increase their differential diagnosis proficiency when managing patients with syncope.</p>
<p><b>2018 CCS/CAIC STEMI GUIDELINE UPDATE</b></p> <p>At the completion of this participation participants will be able to recite and apply the updated CAIC/CCS guidelines when managing the referral of STEMI patients.</p>
<p><b>FRAILTY AND THE CARDIAC PATIENT, WHEN IS ENOUGH ENOUGH OR EVEN TOO MUCH?</b></p> <p>At the completion of this session participants will be able to more effectively define when frailty will be considered and guide treatment decision-making.</p>
<p><b>ECG CHALLENGES; WELLEN'S, DE WINTER'S T WAVE, SGARBOSSA CRITERIA AND OTHERS</b></p> <p>At the completion of this session participants will personally reflect on their diagnostic ECG performance and apply those key learnings within daily practice.</p>
<p><b>FIRST NATIONS EXPERIENCE AND APPROACH TO ILLNESS, TREATMENT AND CULTURAL SAFETY</b></p> <p>At the conclusion of this presentation participants will be able to effectively articulate the aboriginal community needs throughout the patient journey.</p>
<p><b>NEW OPPORTUNITIES IN THE TREATMENT OF DIABETIC PATIENTS</b></p> <p>At the conclusion of this session participants will be able to recite the published SGLT2 evidence and describe patient populations who may benefit most from this therapy.</p>
<p><b>PERIPHERAL VASCULAR DISEASE (PVD), MEDICAL MANAGEMENT INCLUDING WHEN TO CONSIDER ORAL ANTICOAGULATION</b></p> <p>At the conclusion of this session participants will be able to recite the published SGLT2 evidence and describe patient populations who will derive maximal clinical benefit from this therapy.</p>
<p><b>CONGESTIVE HEART FAILURE (CHF) CHALLENGES</b></p> <p>At the conclusion of this session participants will be able to more effectively decrease hospitalizations when managing patients with CHF.</p>
<p><b>MY PATIENT WITH A HEART ATTACK HAD A NORMAL CATH. HOW TO INTERPRET CATH REPORTS</b></p> <p>At the conclusion of this session participants will be able to better interpret and more effectively apply cath lab reports when managing ACS patients</p>
<p><b>3 NEW CLINICAL TRIALS THAT SHOULD CHANGE MY PRACTICE</b></p> <p>At the conclusion of this session participants will be able to critically appraise and apply the conclusions from the three presented clinical trials.</p>